Darvishi B - Search Results

1

Abdolvahab MH, Darvishi B, Zarei M, Majidzadeh-A K, Farahmand L. Abdolvahab MH, et al. Among authors: darvishi b. Immunotherapy. 2020 Aug;12(11):833-855. doi: 10.2217/imt-2019-0217. Epub 2020 Jul 7. Immunotherapy. 2020. PMID: 32635782 Review.

2

Significant Role of MUC1 in Development of Resistance to Currently Existing Anti-cancer Therapeutic Agents.

Farahmand L, Merikhian P, Jalili N, Darvishi B, Majidzadeh-A K. Farahmand L, et al. Among authors: darvishi b. Curr Cancer Drug Targets. 2018;18(8):737-748. doi: 10.2174/1568009617666170623113520. Curr Cancer Drug Targets. 2018. PMID: 28669345 Review.

3

Challenges facing antiangiogenesis therapy: The significant role of hypoxia-inducible factor and MET in development of resistance to anti-vascular endothelial growth factor-targeted therapies.

Mahdi A, Darvishi B, Majidzadeh-A K, Salehi M, Farahmand L. Mahdi A, et al. Among authors: darvishi b. J Cell Physiol. 2019 May;234(5):5655-5663. doi: 10.1002/jcp.27414. Epub 2018 Dec 4. J Cell Physiol. 2019. PMID: 30515806 Review.

4

Probable Mechanisms Involved in Immunotoxin Mediated Capillary Leak Syndrome (CLS) and Recently Developed Countering Strategies.

Darvishi B, Farahmand L, Jalili N, Majidzadeh-A K. Darvishi B, et al. Curr Mol Med. 2018;18(5):335-342. doi: 10.2174/1566524018666181004120112. Curr Mol Med. 2018. PMID: 30289072 Review.

5

Recombinant nanobody against MUC1 tandem repeats inhibits growth, invasion, metastasis, and vascularization of spontaneous mouse mammary tumors.

Merikhian P, Darvishi B, Jalili N, Esmailinejad MR, Khatibi AS, Kalbolandi SM, Salehi M, Mosayebzadeh M, Barough MS, Majidzadeh-A K, Yadegari F, Rahbarizadeh F, Farahmand L. Merikhian P, et al. Among authors: darvishi b. Mol Oncol. 2022 Jan;16(2):485-507. doi: 10.1002/1878-0261.13123. Epub 2021 Nov 19. Mol Oncol. 2022. PMID: 34694686 Free PMC article.

6

Matrix stiffening and acquired resistance to chemotherapy: concepts and clinical significance.

Darvishi B, Eisavand MR, Majidzadeh-A K, Farahmand L. Darvishi B, et al. Br J Cancer. 2022 May;126(9):1253-1263. doi: 10.1038/s41416-021-01680-8. Epub 2022 Feb 5. Br J Cancer. 2022. PMID: 35124704 Free PMC article. Review.

7

Patterns of Cancer Stem Cell Negotiation with Breast Cancer Anti-angiogenic Therapy.

Darvishi B, Farahmand L, Majidzadeh-A K. Darvishi B, et al. Breast J. 2017 Sep;23(5):612-614. doi: 10.1111/tbj.12806. Epub 2017 Mar 30. Breast J. 2017. PMID: 28370769 No abstract available.

8

Stimuli-Responsive Mesoporous Silica NPs as Non-viral Dual siRNA/Chemotherapy Carriers for Triple Negative Breast Cancer.

Darvishi B, Farahmand L, Majidzadeh-A K. Darvishi B, et al. Mol Ther Nucleic Acids. 2017 Jun 16;7:164-180. doi: 10.1016/j.omtn.2017.03.007. Epub 2017 Mar 29. Mol Ther Nucleic Acids. 2017. PMID: 28624192 Free PMC article. Review.

9

NF-κB as the main node of resistance to receptor tyrosine kinase inhibitors in triple-negative breast cancer.

Darvishi B, Farahmand L, Eslami-S Z, Majidzadeh-A K. Darvishi B, et al. Tumour Biol. 2017 Jun;39(6):1010428317706919. doi: 10.1177/1010428317706919. Tumour Biol. 2017. PMID: 28653902 Free article. Review.

10

Recruited bone marrow derived cells, local stromal cells and IL-17 at the front line of resistance development to anti-VEGF targeted therapies.

Darvishi B, Majidzadeh-A K, Ghadirian R, Mosayebzadeh M, Farahmand L. Darvishi B, et al. Life Sci. 2019 Jan 15;217:34-40. doi: 10.1016/j.lfs.2018.11.033. Epub 2018 Nov 22. Life Sci. 2019. PMID: 30472294 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

43 results

Search Page

Filters